U.S. markets close in 4 hours 21 minutes

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.22-0.09 (-1.71%)
As of 11:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.31
Bid5.20 x 3100
Ask5.21 x 1300
Day's Range5.17 - 5.32
52 Week Range2.50 - 6.79
Avg. Volume3,583,956
Market Cap1.217B
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-1.13
Earnings DateOct 27, 2021 - Nov 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AGEN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agenus Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the continuing shift to software; biopharma capital allocation; rising ransomware attacks; and new coverage of Stem, Keysight, and Carlyle Group.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more

    Jensen: How to Play Agenus Using Options

    Agenus , an oncology drug manufacturer, is a good candidate for a simple covered call strategy, argues Real Money's Bret Jensen. This strategy is cheap for investors since the fees for option orders have declined a lot at the majority of brokerages, according to Jensen. "This strategy provides significant downside protection to most holdings within my portfolio," Jensen wrote recently on Real Money.

  • GlobeNewswire

    Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody

    LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash

  • Motley Fool

    2 Stocks Set to Win From the Historic Malaria Vaccine Approval

    Few diseases have wreaked as much havoc as malaria. In 2019, there were an estimated 229 million malaria cases. Last week, the World Health Organization (WHO) recommended widespread use of a malaria vaccine in children.